Previous Article | Next Article 
Journal of Clinical Microbiology, May 2001, p. 1969-1971, Vol. 39, No. 5
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.5.1969-1971.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Use of Recommended Laboratory Testing Methods among
Patients with Tuberculosis in California
Steffi
Kellam,1,
Lisa
Pascopella,1,*
Edward
Desmond,2
Arthur
Reingold,3 and
Daniel P.
Chin1,
Tuberculosis Control
Branch1 and Division of Mycology and
Mycobacteriology,2 California Department of
Health and Human Services, and University of California at
Berkeley School of Public Health,3 Berkeley,
California 94704-1011
Received 27 November 2000/Returned for modification 22 January
2001/Accepted 26 February 2001
 |
ABSTRACT |
This study assessed the extent to which laboratory methods
recommended by the Centers for Disease Control and Prevention were used
in tuberculosis testing of patients in California in 1998. While
recommended methods were used for most patients, there was room for
improvement by hospital and independent non-health maintenance organization laboratories.
 |
TEXT |
The resurgence of drug-susceptible
and multidrug-resistant tuberculosis (MDR-TB) in the United States
between 1985 and 1992 led to new recommendations that urged
laboratories to use more rapid and accurate testing methods for
diagnosing TB (2, 4). Studies assessing the use of
recommended testing methods for TB have consistently shown increases in
the proportion of laboratories adopting rapid methods (1, 3, 5,
6). However, the extent to which laboratory-level improvements
correlate with improvements at the patient level is unknown. TB testing
services are gradually being consolidated in a smaller number of
laboratories; consequently, a few laboratories using less rapid testing
procedures now have the potential to disproportionately affect the
quality of testing for a large proportion of TB patients.
In 1998, TB cases in California represented approximately 20% of all
the TB cases in the United States (Centers for Disease Control and
Prevention [CDC], www.cdc.gov/nchstp/tb/surv/surv.htm). That
year, we conducted a study to assess the use of recommended testing
methods for California patients with culture-confirmed TB and to
evaluate the testing procedures of the mycobacteriology laboratories
that performed the tests for those patients.
Study population.
The study population comprised 300 culture-confirmed cases of TB reported to the TB control programs in
Los Angeles, Riverside, San Francisco, and Santa Clara counties between
1 January and 31 December 1998. In 1998, 48% of California's TB cases
were reported in these counties. We selected the first 75 culture-confirmed cases reported in each county during the study
period. Because only 68 cases were reported in Riverside County during
1998, 7 additional cases were selected from Los Angeles County. These two counties are adjacent to each other and have similar populations.
TB testing laboratories.
Fifty-five separate laboratories were
identified through patient records as having performed primary TB
testing for one or more of the study patients. If a patient had many
specimens tested for TB, the specimen with the earliest test result was
selected for this evaluation. The laboratories that served the patient sample included 7 (13%) public health laboratories, 2 (4%) health maintenance organization (HMO) laboratories, 11 (20%) independent non-HMO laboratories, and 35 (64%) hospital laboratories.
Laboratory-specific calculations are based on 54 laboratories
because one hospital laboratory declined to participate in
the study. In addition to patient-specific data, each laboratory was
asked to complete a questionnaire concerning laboratory practices,
including the range of testing services performed and monthly volume of
specimens processed in that laboratory.
Completeness of data.
Information on the testing method used
was available for 268 (89%) of the 300 patients for smear microscopy,
265 (88%) of the 300 patients for mycobacterial culture, 272 (91%) of the 300 patients for identification of M. tuberculosis, and 266 (89%) of the 300 patients for drug
susceptibility testing. Unless otherwise noted, patient-specific
analyses are based on these denominators. Analyses were performed using
SAS 6.12 (SAS Institute, Cary, N.C.). If information on a specific
variable was missing for a laboratory or a patient, the laboratory or
patient was excluded from analyses relating to that variable; for this
reason, denominators for different analyses may vary.
Comparison of laboratories performing TB testing and patient
specimens tested by those laboratories.
In some cases, a small
proportion of the laboratories was responsible for testing a relatively
large proportion of patient specimens for TB (Table
1). Public health and HMO laboratories accounted for <15% of the laboratories performing smear microscopy and mycobacterial culture, but they tested more than one-third of the
patient specimens in our study population. Although most (60 to 90%)
laboratories performing TB testing were either hospital or independent
non-HMO laboratories, they performed a relatively smaller proportion of
testing. Even so, these laboratories performed more than half of all TB
testing.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Proportion of laboratories performing TB testing,
compared with the proportion of TB patients tested by these
laboratories, by laboratory type
|
|
Use of recommended testing methods.
Most of the study patients
were tested using CDC recommended methods (Table
2). In general, the proportion of
laboratories that performed TB testing using recommended methods
correlated closely with the proportion of patients tested using those
methods (Table 3). However,
differences in these proportions were noted for smear microscopy,
mycobacterial culture, and drug susceptibility testing. With regard to
smear microscopy and culture testing, hospital laboratories largely
accounted for these discrepancies. For drug susceptibility testing in
independent non-HMO laboratories, the proportion of patients tested
using BACTEC was lower than the proportion of laboratories that used
this method. These differences suggest that laboratory-level surveys
may yield inaccurate estimates of the proportion of patients tested
using recommended methods.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Testing methods for smear microscopy, mycobacterial
culture, identification of M. tuberculosis and drug
susceptibility testing of patient specimens
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Proportion of laboratories using recommended methods for
TB testing compared with the proportion of patients tested using
recommended methods by laboratory type
|
|
Hospital laboratories that did not use recommended methods for TB
testing generally processed a lower volume of specimens (Table
4). Public health and HMO laboratories
were most likely to adhere to all of the recommended methods for TB
testing. These laboratories generally processed large volumes of
specimens for TB testing (>300 specimens per month in most cases) and
performed the full range of TB testing in house.
View this table:
[in this window]
[in a new window]
|
TABLE 4.
Comparison of hospital laboratories using or not using
recommended testing methods for smear microscopy and culture, by
average monthly volume of specimens processed for TB testing
|
|
Areas for improvement.
Our results suggest that efforts to
further expand the use of recommended methods for smear microscopy and
mycobacterial culture should focus on hospital laboratories. Whereas
other laboratories adhered to the use of recommended methods for these
tests, a large proportion of hospital laboratories did not use a
fluorochrome method for the initial smear and/or liquid medium for
mycobacterial culture.
Efforts to further expand the use of recommended methods for drug
susceptibility testing could focus on independent non-HMO laboratories.
In our study, a lower proportion of patients in independent non-HMO
laboratories was tested using BACTEC compared with patients tested in
other laboratories. In California, the task of improving or monitoring
the adherence to recommended drug susceptibility testing methods
is facilitated by the relatively small number of laboratories involved
with this type of testing.
Study limitations.
First, although the sample included 300 patients, testing for these patients was performed in a small number of
public health, HMO, and independent non-HMO laboratories. Therefore,
our results may not provide an accurate portrayal of laboratory testing
procedures. For example, assessment of the role of specimen volume in
the use of recommended testing methods for smear microscopy and culture in hospital labs was limited by the small number of hospital
laboratories used in the analysis. However, our results do agree with
the results from previous studies showing that hospital laboratories
processing fewer specimens were less likely to use recommended testing
methods for smear microscopy and culture (6).
Second, data obtained from laboratories that tested a small number of
patients may not accurately describe the testing practices in these
laboratories. Some laboratories did not always use the same testing
method for all specimens tested in those laboratories. Therefore, it
may not be appropriate to assume a laboratory did or did not comply
with recommended testing practices based on data from a few patients.
Summary.
Our findings suggest that most patients undergoing
evaluation for TB in California are tested using CDC-recommended
laboratory methods. These analyses also indicate that results based on
surveys at the laboratory level may not accurately reflect results at the patient level. Future efforts to expand the use of recommended methods for smear microscopy and mycobacterial culture should focus on
low-volume hospital laboratories, and for drug susceptibility testing
the focus should be on independent non-HMO laboratories.
 |
ACKNOWLEDGMENTS |
This work was supported by a cooperative agreement, M2854, from the
Association of Public Health Laboratories.
We thank the members of the Advisory Committee convened by the
Association of Public Health Laboratories during the design of this
study and for their assistance with piloting the study questionnaire.
We also thank Peter Oh for assistance with data collection and
management, Sarah Royce for critical reading of the manuscript, the
four county TB control programs that participated in the study, and all
of the laboratory personnel who facilitated our access to patient
laboratory records and who completed and returned the questionnaires.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: California
Department of Health Services, Tuberculosis Control Branch, 2151 Berkeley Way, Rm. 608, Berkeley, CA 94704-1011. Phone: (510) 540-3585. Fax: (510) 849-5269. E-mail: Lpascope{at}dhs.ca.gov.
Present address: 155 Primrose La., Fredericksburg, TX 78624.
Present address: World Health Organization, 100600 Beijing, China.
 |
REFERENCES |
| 1.
|
Bird, B. R.,
M. M. Denniston,
R. E. Huebner, and R. C. Good.
1996.
Changing practices in mycobacteriology: a follow-up survey of state and territorial public health laboratories.
J. Clin. Microbiol.
34:554-559[Abstract].
|
| 2.
|
Centers for Disease Control and Prevention.
1992.
National action plan to combat multidrug-resistant tuberculosis.
Morb. Mortal. Wkly. Rep.
41(RR-11):1-48.
|
| 3.
|
Denniston, M. M.,
B. R. Bird, and K. A. Kelley.
1997.
Contrast of survey results between state and a cohort of nonstate mycobacteriology laboratories: changes in laboratory practices.
J. Clin. Microbiol.
35:422-426[Abstract].
|
| 4.
|
Tenover, F. C.,
J. T. Crawford,
R. E. Huebner,
L. J. Geiter,
C. R. Horsburgh, Jr., and R. C. Good.
1993.
The resurgence of tuberculosis: is your laboratory ready?
J. Clin. Microbiol.
31:767-770[Free Full Text].
|
| 5.
|
Tokars, J. I.,
J. R. Rudnick,
K. Kroc,
L. Manangan,
G. Pugliese,
R. E. Huebner,
J. Chan, and W. R. Jarvis.
1996.
U.S. hospital mycobacteriology laboratories: status and comparison with state public health department laboratories.
J. Clin. Microbiol.
34:680-685[Abstract].
|
| 6.
|
Woods, G. L.,
T. A. Long, and F. G. Witebsky.
1996.
Mycobacterial testing in clinical laboratories that participate in the College of American Pathologists mycobacteriology surveys.
Arch. Pathol. Lab. Med.
120:429-435[Medline].
|
Journal of Clinical Microbiology, May 2001, p. 1969-1971, Vol. 39, No. 5
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.5.1969-1971.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Pascopella, L., Kellam, S., Ridderhof, J., Chin, D. P., Reingold, A., Desmond, E., Flood, J., Royce, S.
(2004). Laboratory Reporting of Tuberculosis Test Results and Patient Treatment Initiation in California. J. Clin. Microbiol.
42: 4209-4213
[Abstract]
[Full Text]